Skip to main content

Table 5 Comparison of drop-out rate mean values and reasons between NEONet database and published Real-life studies

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

 

NEONet

Real-life

p-value

Drop-out

31.67 %

17.50 %

0.0000

Patient decision

48.57 %

35.01 %

0.0160

Lack of efficacy

25.71 %

23.53 %

0.3475

Adverse events

7.14 %

12.04 %

0.1176

Other causes

18.57 %

29.41 %

0.0318